转自：医药观澜

“全球互联互通，智者就总能找到共赢之路，这正是今天活动的意义所在。”——瑞士生物科技协会首席执行官Michael Altorfer博士

瑞士是全球最具创新活力的生物医药产业重镇之一，连续14年位居世界知识产权组织（WIPO）评选的全球创新指数榜首。依托于当地科研机构、生物医药公司紧密交织的研发网络，以及高度国际化的合作环境，这片土地上蕴育了大量突破性疗法。罗氏和诺华等大型跨国药企也扎根于此，使得瑞士成为了全球医药创新与合作的重要策源地。

作为创新赋能者、客户信赖的合作伙伴以及全球医药及生命科学行业的贡献者，药明康德已深深融入这一充满活力的创新生态系统——我们在瑞士库威的基地于2024年实现产能翻倍，更好地赋能来自瑞士、欧洲乃至全球的客户；而作为瑞士生物科技协会的成员，药明康德也以其独特方式，积极促进当地生态圈的蓬勃发展。今年的瑞士生物技术日期间，药明康德延续惯例，与来自全球的生态圈伙伴共话合作创新，共求协作进步。

▲药明康德巴塞尔生态圈活动速览

来自瑞士当地的生物公司新锐、欧洲扶植早期创新的风投、以及全球创新技术的领军企业的嘉宾在交流中致辞，强调了全球合作的重要意义。

Alentis Therapeutics首席科学官Alberto Toso博士回顾了公司发展的非凡历程。当他作为第九位员工加入公司时，Alentis尚未建立肿瘤研发管线，也没有明确的发展路径。他们拥有的，只是挑战CLDN1这一全新肿瘤靶点的勇气，以及开发抗体偶联药物（ADC）的想法。在药明康德等合作伙伴的协助下，Alentis快速将创新想法变为现实，开发了两款潜在“first-in-class”的ADC药物。2024年，这家公司完成逾1.8亿美元的D轮融资，金额为去年瑞士生物技术产业之最。“我想感谢药明康德这样的合作伙伴，他们对我们ADC疗法的开发至关重要。如果没有他们协助，这一切不会成真。”

Karen Wagner博士早年曾任职于GlycArt Biotechnology，是瑞士第一代生物科技创业浪潮的先驱之一。如今，作为西班牙规模最大的生命科学风投公司Ysios Capital的管理合伙人，Wagner博士强调了早期投资对于生物技术创新的重要意义——“越是在人们惧怕风险的时候，越需要支持早期创新。”她指出，支持早期生物科技公司，不仅需要精准的资本投入，更需要运营上的深度支持。这包括与创始人一道组建团队、制定战略，激发新锐的完整潜力。尽管当下充满了种种不确定性，但生物医药依旧是一个值得长期支持的产业。Ysios Capital管理基金超4亿欧元，近期还全新推出公募基金和聚焦技术转让的专项基金，以在欧洲和全球推动更多创新项目。

站在全球科技前沿，英伟达（NVIDIA）欧洲、中东和非洲地区（EMEA）医疗与生命科学负责人Eva-Maria Hempe博士则分享了数据和计算技术对新药研发的变革潜力。她指出，早期炼金术士试图“点石成金”，背后反映的是化学知识的匮乏。如今的医药人很像“炼金术士”，对疾病背后生物学的认知还不够深入。而创新技术能够帮助我们更深入地理解生物学机制，为新药研发带来宝贵洞见。当产业拥有海量且优质的数据、强大的算力、以及智能的算法，并在开放协作的氛围中并肩而行，产业有信心在新药研发中走出一条完全不同的新道路。

正如Altorfer博士在药明康德早餐会上所强调，创新是一项全球事业。我们常说，“一个孩子的成长需要一个村庄。”在生物科技行业，推动科学发现转化为改变生命的药物，同样需要一个“全球村”——汇聚高瞻远瞩的科学家、富有魄力的投资人和靠谱的合作伙伴，共同携手前行。他也特别谈到，在协会多年发展中，药明康德始终是瑞士生物技术协会长期互信合作的伙伴。

药明康德副总裁蔡辉博士代表公司感谢在场的所有嘉宾和产业领袖。药明康德一路走来，离不开全球所有合作伙伴的信任和支持，公司2025年第一季度收入及利润均重回双位数增长，这样的韧性发展，也离不开全球生态圈合作创新。药明康德的Dave Madge博士，Thomas Meins博士，以及Vikalp Mohan先生也分别介绍了公司的瑞士和德国基地如何更好地赋能欧洲当地，乃至全球的客户。药明康德将持续依托全球研发基地与生产网络，以独特的CRDMO“一体化、端到端”模式，为合作伙伴提供高效、灵活的解决方案。

展望未来，药明康德将继续坚定履行使命：拥抱技术、赋能生态，并携手全球伙伴，共同实现“让天下没有难做的药，难治的病”的愿景。

It Takes a Global Village: WuXi Executive Breakfast in Switzerland

“I’m delighted to welcome you to the most international Swiss Biotech Day ever. Smart people who are globally connected always find ways to work together. That’s what today is all about.”— Dr. Michael Altorfer, CEO, Swiss Biotech Association

Switzerland stands as one of the world’s most respected and innovative biotech hubs. Home to global pharmaceutical leaders such as Roche and Novartis, the country has long championed the development of breakthrough therapies through deep international collaboration—a philosophy that continues to define its global influence.

At WuXi AppTec, we are proud to be part of this dynamic landscape—not only through our operations in Couvet, Switzerland, but also as an engaged member of the Swiss Biotech Association. Alongside this year’s Swiss Biotech Day 2025, we were honored to host our annual WuXi Executive Breakfast in Basel, a tradition bringing together partners, customers, and friends to celebrate a shared commitment to innovation, collaboration, and progress.

From leading Swiss biotech companies to pan-European investors and global tech innovators, this year, we featured a distinguished lineup of speakers who offered forward-looking perspectives on the future of science and innovation:

Dr. Alberto Toso, Chief Scientific Officer of Alentis Therapeutics, reflected on the company’s extraordinary journey. When he joined as the ninth employee, Alentis had no oncology pipeline, no clinical data, and no clear roadmap—only a small, ambitious team determined to pursue CLDN1, a novel target in oncology. With courage, strategic collaborations, and rapid execution, the company progressed from concept to clinic in under three years and recently closed a $181.4 million Series D—the largest biotech financing in Switzerland in 2024. Dr. Toso also expressed his gratitude to WuXi AppTec and other partners whose support helped turn that vision into reality.

Dr. Karen Wagner, a pioneer in Switzerland’s first wave of biotech innovation, emphasized the critical need for sustained investment in early-stage companies—when people fear risk, early-stage investment becomes even more vital. Now Managing Partner at Ysios Capital, she underlined the importance of combining focused capital with hands-on operational support—building teams, shaping strategy, and working closely with founders to unlock potential.

Dr. Eva-Maria Hempe, Head of Healthcare & Life Sciences EMEA at NVIDIA, brought a technological lens to the conversation—joking that she’s often asked what a “computer gaming company” is doing at biotech conferences. She made the case that biotech today often feels like early alchemy—rich in correlations but lacking causality. With the right infrastructure, open collaboration, and advanced technology, we are now on the cusp of transforming drug discovery through true biological insight.

We often say, “it takes a village to raise a child.” In biotech, it takes a Global Village—a diverse network of visionary scientists, dedicated partners, and bold investors—to transform discovery into life-changing medicines.

Looking ahead, WuXi AppTec remains steadfast in our mission: to embrace technology, empower the ecosystem, and help realize the vision that “every drug can be made and every disease can be treated.”

（转自：医药观澜）